Editorial: Antimicrobial resistance and therapy in critically ill patients, volume II
By
Xiao-Hong Zhou
Zhi-Tao Yang
Shun-Jin Zhao
Qi Li
Jian-Cang Zhou
June 25, 2026
Clinical Scorecard: Editorial: Addressing Antimicrobial Resistance and Treatment Strategies in Severely Ill Patients, Volume II
At a Glance
Category Detail
Condition Antimicrobial resistance in critically ill patients Key Mechanisms Multidrug-resistant pathogens, precision dosing, and novel disinfection strategies Target Population Critically ill patients with infections Care Setting Critical care
Key Highlights
MDR pathogens infections are a pressing challenge in critically ill patients. Colistin sulfate shows a lower risk of acute kidney injury compared to polymyxin B. Adjunctive aerosolized polymyxin B improves microbial eradication in severe pneumonia. Therapeutic drug monitoring enhances dosing accuracy for daptomycin in critically ill patients. Cold atmospheric-pressure plasma effectively inactivates MDR pathogens on hospital surfaces. Guideline-Based Recommendations
Diagnosis
Utilize precision therapeutic drug monitoring for accurate dosing. Management
Consider inhaled polymyxins as an adjuvant therapy for severe pneumonia. Monitoring & Follow-up
Implement AUC-guided dosing for vancomycin and monitor daptomycin levels. Risks
Be aware of the increased risk of acute kidney injury with certain antibiotics. Patient & Prescribing Data
Patients with multidrug-resistant infections in critical care settings
Loading doses and combination therapies are critical for effective treatment.
Clinical Best Practices
Adopt individualized antibiotic dosing based on pharmacokinetic and pharmacodynamic insights. Standardize guidelines for treatment of rare pathogens. Related Resources & Content
